Neuroendocrine neoplasms of the lung represent about 20% to 30% of all neuroendocrine tumors. On the basis of clinical and pathologic characteristics, 2 different categories of tumors may be defined: poorly differentiated neuroendocrine neoplasms, characterized by a high rate of recurrences and poor prognosis, and well-differentiated neuroendocrine neoplasms (typical carcinoids and atypical carcinoids), which generally display an indolent course. Lung carcinoids represent only 1% to 5% of all lung malignancies, but their incidence has significantly increased over the past 30 years. Surgery is the reference standard of treatment for lung carcinoids with locoregional disease. For advanced or unresectable lung carcinoids, several therapeutic options are available, but the choice should be shared within a multidisciplinary team to ensure optimal therapeutic outcomes. We describe the current management of these rare neoplasms.

Recent Advances in the Management of Typical and Atypical Lung Carcinoids / N. Prinzi, R.E. Rossi, C. Proto, G. Leuzzi, A. Raimondi, M. Torchio, M. Milione, F. Corti, E. Colombo, M. Prisciandaro, T. Cascella, C. Spreafico, T. Beninato, J. Coppa, G. Lo Russo, M. Di Bartolomeo, F. de Braud, S. Pusceddu. - In: CLINICAL LUNG CANCER. - ISSN 1525-7304. - 22:3(2021 May), pp. 161-169. [10.1016/j.cllc.2020.12.004]

Recent Advances in the Management of Typical and Atypical Lung Carcinoids

Rossi R. E.;Torchio M.;Prisciandaro M.;Spreafico C.;Beninato T.;de Braud F.;
2021-05

Abstract

Neuroendocrine neoplasms of the lung represent about 20% to 30% of all neuroendocrine tumors. On the basis of clinical and pathologic characteristics, 2 different categories of tumors may be defined: poorly differentiated neuroendocrine neoplasms, characterized by a high rate of recurrences and poor prognosis, and well-differentiated neuroendocrine neoplasms (typical carcinoids and atypical carcinoids), which generally display an indolent course. Lung carcinoids represent only 1% to 5% of all lung malignancies, but their incidence has significantly increased over the past 30 years. Surgery is the reference standard of treatment for lung carcinoids with locoregional disease. For advanced or unresectable lung carcinoids, several therapeutic options are available, but the choice should be shared within a multidisciplinary team to ensure optimal therapeutic outcomes. We describe the current management of these rare neoplasms.
Bronchial neuroendocrine tumors; Diagnosis; Epidemiology; Therapy; Typical carcinoid; Carcinoid Tumor; Humans; Incidence; Lung Neoplasms; Neuroendocrine Tumors; Patient Care Team
Settore MED/06 - Oncologia Medica
giu-2020
Article (author)
File in questo prodotto:
File Dimensione Formato  
recent Advances.pdf

solo utenti autorizzati

Tipologia: Publisher's version/PDF
Dimensione 335.97 kB
Formato Adobe PDF
335.97 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/908334
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 6
social impact